Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.37 |
| ▸ | PDE5A | O76074 | 3/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL64360 | 0.88 | CYP2C9 (0.40) | CYP2C9KCNH2GAANPSR1LMNA | |
| SCHEMBL88284 | 0.88 | PDE5A (0.35) | CYP2C9KCNH2PDE5AGAANPSR1 | |
| SCHEMBL64097 | 0.88 | PDE5A (0.35) | CYP2C9KCNH2PDE5AGAANPSR1 | |
| SCHEMBL64620 | 0.88 | PDE5A (0.35) | CYP2C9KCNH2PDE5AGAANPSR1 | |
| SCHEMBL64365 | 0.87 | MMP13 (0.34) | CYP2C9PDE5ASMN1; SMN2 | |
| SCHEMBL62845 | 0.86 | CYP2C9 (0.55) | CYP2C9KCNH2GAANPSR1MEN1 | |
| SCHEMBL64026 | 0.81 | CYP2C9 (0.44) | CYP2C9KCNH2PDE5A | |
| SCHEMBL62502 | 0.80 | CYP2C9 (0.46) | CYP2C9KCNH2LMNA | |
| SCHEMBL64015 | 0.80 | CYP2C9 (0.49) | CYP2C9KCNH2GAANPSR1MEN1 | |
| SCHEMBL63588 | 0.79 | CYP2C9 (0.54) | CYP2C9KCNH2GAANPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | CYP2C9 602/4885KCNH2 3969/4885PDE5A 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.